+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hepatitis A Inactivated Vaccine Market - Global Forecast 2026-2032- Product Image
Hepatitis A Inactivated Vaccine Market - Global Forecast 2026-2032- Product Image
Sale

Hepatitis A Inactivated Vaccine Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6143091
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Hepatitis A Inactivated Vaccine Market is projected to reach USD 819.90 Million in 2026. It is expected to continue growing at a CAGR of 8.61%, reaching USD 1.37 Billion by 2032.

Hepatitis A Inactivated Vaccine: Executive Summary

Hepatitis A inactivated vaccines are administered to prevent infection by hepatitis A virus, a fecal-oral pathogen associated with contaminated food, water, and close personal contact. The public-health role of vaccination differs by jurisdiction according to endemicity, sanitation, travel patterns, outbreak history, immunization policy, and access to healthcare. This summary focuses on evidence-based strategic considerations without presenting market estimates, shares, forecasts, or company-specific analysis.

Public-Health Priorities Are Reshaping Vaccine Delivery

The landscape is shifting from isolated travel vaccination toward broader risk-based prevention. Routine childhood immunization, vaccination of people at elevated risk of severe disease, outbreak response, occupational and institutional programs, and protection of travelers increasingly operate as complementary channels. Persistent differences in hepatitis A incidence, water and sanitation infrastructure, and adult immunization practices continue to influence policy design. Supply continuity, clear eligibility guidance, cold-chain reliability, and rapid outbreak coordination remain central operational requirements.

Artificial Intelligence Strengthens Surveillance and Program Execution

Artificial intelligence can support hepatitis A prevention by improving analysis of case reports, laboratory results, geographic clustering, vaccination records, and environmental indicators. Predictive tools may help public-health teams identify unusual transmission patterns, prioritize investigations, and target risk communication. In immunization operations, AI can assist with appointment optimization, reminder systems, inventory monitoring, and documentation quality. These applications require representative data, privacy safeguards, clinical validation, transparent governance, and human review because biased or incomplete records can misdirect resources and amplify inequities.

Regional Differences Define Prevention and Access Strategies

North America combines routine or risk-based vaccination with strong surveillance, travel-health services, and outbreak response, while access and adult uptake can vary by jurisdiction and population. Latin America’s priorities include protecting children and communities affected by uneven sanitation, addressing outbreaks, and maintaining reliable immunization delivery. Europe reflects differing national schedules, travel patterns, and approaches to vaccinating high-risk groups. The Middle East requires attention to mobility, pilgrimage and mass gathering settings, food and water safety, and outbreak preparedness. Africa faces substantial heterogeneity in endemicity, sanitation, health-system capacity, and vaccine access, making integrated prevention especially important. Asia-Pacific spans highly diverse epidemiological conditions and includes settings where routine programs, travel vaccination, outbreak control, and improvements in water and sanitation must be coordinated.

Multilateral Groups Shape Policy Coordination and Implementation

ASEAN cooperation is relevant to cross-border surveillance, travel, outbreak communication, and immunization access across countries with varied epidemiological conditions. BRICS members can contribute to collaboration on manufacturing capacity, procurement resilience, surveillance, and research while recognizing substantial differences among national programs. The European Union benefits from coordinated health-security mechanisms, although vaccination schedules and delivery remain primarily national responsibilities. G7 coordination is relevant to surveillance standards, emergency preparedness, health-system resilience, and support for global immunization efforts. GCC countries must account for high mobility, expatriate populations, pilgrimage-related travel, and concentrated healthcare delivery. NATO’s relevance is primarily through force health protection, operational readiness, deployment medicine, and continuity of essential vaccination services.

Country Contexts Require Distinct Immunization Approaches

Australia emphasizes routine childhood protection, travel health, outbreak management, and access across geographically dispersed communities. Brazil combines national immunization infrastructure with regional variation in sanitation, surveillance, and outbreak risk. Canada must address provincial and territorial differences, travel vaccination, remote access, and outbreak response. China’s approach reflects large population scale, regional diversity, routine prevention, and control of food- and water-associated transmission. France, Germany, Italy, and Spain balance national guidance, European travel, risk-based vaccination, and localized outbreak preparedness. India’s priorities include sanitation improvement, surveillance, childhood and high-risk-group protection, and equitable delivery across diverse settings. Japan and South Korea integrate travel-related prevention, public-health surveillance, and national guidance within advanced healthcare systems. Mexico combines routine and targeted prevention with attention to regional disparities and travel exposure. Russia’s planning must account for regional variation, healthcare access, and outbreak surveillance. The United Kingdom emphasizes national immunization guidance, travel health, risk-group protection, and rapid local response. The United States uses routine and risk-based recommendations, travel vaccination, outbreak interventions, and jurisdictional public-health coordination.

Leadership Actions to Improve Hepatitis A Vaccine Impact

Industry and public-health leaders should align product access, evidence generation, and delivery operations with local epidemiology rather than applying a uniform model. Priorities include strengthening demand and supply visibility, supporting cold-chain and stock-management practices, simplifying eligibility and completion guidance, and partnering with health authorities on outbreak readiness. Programs should combine vaccination with safe water, sanitation, food-safety measures, testing, case investigation, and risk communication. Leaders should also measure coverage and completion across underserved groups, evaluate real-world effectiveness, establish responsible AI governance, and maintain transparent safety communication. Cross-border coordination is particularly important for travel corridors, migrant populations, mass gatherings, and military deployments.

Evidence-Based Methodology for the Executive Summary

This summary uses the supplied market definition-hepatitis A inactivated vaccine-and organizes the assessment across epidemiology, immunization policy, delivery systems, regional conditions, multinational groupings, and named countries. The interpretation is grounded in established public-health principles concerning hepatitis A transmission, vaccination, surveillance, outbreak control, sanitation, and health-system implementation. It deliberately excludes market estimates, market sizing, market shares, forecasts, and company-specific claims. Country and group observations are presented as strategic context and should be validated against current national schedules, regulatory guidance, surveillance reports, and local procurement information before operational decisions are made.

Coordinated Prevention Will Determine Long-Term Effectiveness

The strategic importance of inactivated hepatitis A vaccination is closely tied to prevention systems rather than vaccination alone. Effective outcomes depend on matching schedules and risk-based policies to local epidemiology, ensuring dependable access, integrating vaccination with sanitation and outbreak control, and using surveillance data responsibly. Regional, group, and country differences require tailored implementation, while artificial intelligence can improve execution only when supported by high-quality data and accountable oversight. Leaders that connect policy, supply, delivery, and public-health infrastructure will be better positioned to reduce transmission and protect populations at elevated risk.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Hepatitis A Inactivated Vaccine Market, by Age Group
7.1. Introduction
7.2. Adult
7.3. Geriatric
7.4. Pediatric
8. Hepatitis A Inactivated Vaccine Market, by Product Type
8.1. Introduction
8.2. Multi Dose Vial
8.3. Single Dose Vial
9. Hepatitis A Inactivated Vaccine Market, by Application
9.1. Introduction
9.2. Post-Exposure Prophylaxis
9.3. Pre-Exposure Prophylaxis
10. Hepatitis A Inactivated Vaccine Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Diagnostic Centers
10.4. Hospitals
11. Hepatitis A Inactivated Vaccine Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Hepatitis A Inactivated Vaccine Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Hepatitis A Inactivated Vaccine Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Hepatitis A Inactivated Vaccine Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Beijing Institute of Biological Products Co., Ltd.
16.2. Bharat Biotech International Limited
16.3. Changchun Institute of Biological Products Co., Ltd.
16.4. Chongqing Zhifei Biological Products Co., Ltd.
16.5. GlaxoSmithKline Biologicals SA
16.6. Merck & Co., Inc.
16.7. Panacea Biotec Limited
16.8. PT Bio Farma (Persero)
16.9. Sanofi Pasteur SA
16.10. SK Bioscience Co., Ltd.
16.11. Valneva SE
16.12. Walvax Biotechnology Co., Ltd.
16.13. Zhejiang Kangtai Biological Products Co., Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Hepatitis A Inactivated Vaccine Market, Years Considered for the Study
FIGURE 2. Global Hepatitis A Inactivated Vaccine Market, Research Design
FIGURE 3. Global Hepatitis A Inactivated Vaccine Market, Research Framework
FIGURE 4. Global Hepatitis A Inactivated Vaccine Market, Data Triangulation
FIGURE 5. Global Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 7. Global Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 9. Global Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Hepatitis A Inactivated Vaccine Market Size, by Application, 2025 vs 2032 (%)
FIGURE 11. Global Hepatitis A Inactivated Vaccine Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Hepatitis A Inactivated Vaccine Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Hepatitis A Inactivated Vaccine Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Hepatitis A Inactivated Vaccine Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Hepatitis A Inactivated Vaccine Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Hepatitis A Inactivated Vaccine Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Hepatitis A Inactivated Vaccine Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Hepatitis A Inactivated Vaccine Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Hepatitis A Inactivated Vaccine Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Hepatitis A Inactivated Vaccine Market Segmentation & Coverage
TABLE 2. Global Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 3. Global Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 4. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 14. Global Multi Dose Vial Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Multi Dose Vial Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Multi Dose Vial Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Single Dose Vial Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Single Dose Vial Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Single Dose Vial Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 21. Global Post-Exposure Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Post-Exposure Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Post-Exposure Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Pre-Exposure Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Pre-Exposure Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Pre-Exposure Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 28. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Diagnostic Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Diagnostic Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Diagnostic Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 38. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Asia-Pacific Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Asia-Pacific Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 50. Asia-Pacific Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 54. North America Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. North America Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 56. North America Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 57. North America Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 58. North America Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 59. North America Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 60. Latin America Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Latin America Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 62. Latin America Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 63. Latin America Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 64. Latin America Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 65. Latin America Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 66. Europe Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Europe Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 68. Europe Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 69. Europe Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 70. Europe Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. Europe Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 72. Middle East Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Middle East Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 74. Middle East Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 75. Middle East Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 76. Middle East Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 77. Middle East Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 78. Africa Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Africa Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 80. Africa Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 81. Africa Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 82. Africa Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 83. Africa Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 84. Global Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. ASEAN Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. ASEAN Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 87. ASEAN Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 88. ASEAN Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 89. ASEAN Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. ASEAN Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 91. GCC Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. GCC Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 93. GCC Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 94. GCC Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 95. GCC Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 96. GCC Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 97. European Union Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. European Union Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 99. European Union Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 100. European Union Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 101. European Union Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. European Union Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 103. BRICS Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. BRICS Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 105. BRICS Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 106. BRICS Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 107. BRICS Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. BRICS Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 109. G7 Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. G7 Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 111. G7 Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 112. G7 Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 113. G7 Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. G7 Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 115. NATO Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. NATO Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 117. NATO Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 118. NATO Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 119. NATO Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. NATO Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 121. Global Hepatitis A Inactivated Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. United States Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 123. United States Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 124. United States Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 125. United States Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 126. United States Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. United States Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 128. Canada Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 129. Canada Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 130. Canada Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 131. Canada Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 132. Canada Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 133. Canada Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. Mexico Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 135. Mexico Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 136. Mexico Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 137. Mexico Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 138. Mexico Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 139. Mexico Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 140. Brazil Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 141. Brazil Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 142. Brazil Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 143. Brazil Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 144. Brazil Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. Brazil Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 146. United Kingdom Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 147. United Kingdom Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 148. United Kingdom Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 149. United Kingdom Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 150. United Kingdom Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. United Kingdom Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 152. Germany Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 153. Germany Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 154. Germany Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 155. Germany Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 156. Germany Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. Germany Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 158. France Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 159. France Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 160. France Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 161. France Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 162. France Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. France Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 164. Russia Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 165. Russia Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 166. Russia Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 167. Russia Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 168. Russia Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Russia Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. Italy Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 171. Italy Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 172. Italy Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 173. Italy Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 174. Italy Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. Italy Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 176. Spain Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 177. Spain Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 178. Spain Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 179. Spain Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 180. Spain Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. Spain Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 182. China Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 183. China Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 184. China Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 185. China Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 186. China Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. China Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. India Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 189. India Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 190. India Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 191. India Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 192. India Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. India Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. Japan Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 195. Japan Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 196. Japan Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 197. Japan Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 198. Japan Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. Japan Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 200. Australia Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 201. Australia Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 202. Australia Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 203. Australia Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 204. Australia Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Australia Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 206. South Korea Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
TABLE 207. South Korea Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 208. South Korea Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 209. South Korea Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
TABLE 210. South Korea Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. South Korea Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. Global Hepatitis A Inactivated Vaccine Market Share, by Key Player, 2025
TABLE 213. Global Hepatitis A Inactivated Vaccine Market, Key Experts

Companies Mentioned

  • Beijing Institute of Biological Products Co., Ltd.
  • Bharat Biotech International Limited
  • Changchun Institute of Biological Products Co., Ltd.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • GlaxoSmithKline Biologicals SA
  • Merck & Co., Inc.
  • Panacea Biotec Limited
  • PT Bio Farma (Persero)
  • Sanofi Pasteur SA
  • SK Bioscience Co., Ltd.
  • Valneva SE
  • Walvax Biotechnology Co., Ltd.
  • Zhejiang Kangtai Biological Products Co., Ltd.

Related Topics

Related Reports

Hepatitis A Vaccines Market - Global Strategic Business Report - Product Image

Hepatitis A Vaccines Market - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Adult Vaccines Market - Global Forecast 2026-2032 - Product Image

Adult Vaccines Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Hepatitis A Market - A Global and Regional Analysis: Focus on Vaccine Type, Application, Country, 2026-2036 - Product Image

Hepatitis A Market - A Global and Regional Analysis: Focus on Vaccine Type, Application, Country, 2026-2036

  • Report
  • Global
From
Inactivated Vaccines Market Report 2026 - Product Image

Inactivated Vaccines Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Inactivated Vaccines Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Inactivated Vaccines Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.